Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Furthermore, studies have found that GLP-1 receptor agonists can support cardiovascular health by lowering blood pressure, improving cholesterol levels, and reducing the risk of heart disease
Side effects include injection-site reactions, cold-like symptoms, and mild muscle aches
Losing 5 to 10 percent of body weight can lead to a decreased risk of cardiovascular disease in adults who are overweight or obese
2008 Jul;43(1):1-14
This is particularly relevant with the recent approval of Rezdiffra (resmetirom, Madrigal Pharmaceuticals), which has both a fibrosis and MASH benefit
This highlights the need to balance the benefits and disadvantages of such use and to regularly reassess the need for continued proton pump inhibitor treatment. The research was published in The British Medical Journal (BMJ)
